Endocannabinoids

Psychosis and Schizophrenia

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

schizophrenia is a chronic mental disorder that affects around 1% of the worldwide population. It causes psychotic behaviors, social and emotional disruptions and different cognitive impairments.

The causes of the disease are still not clear but studies show that both genetic and environmental factors have an effect on it.

DHEA

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

Docosahexaenoylethanolamine is an endocannabinoid that is synthesized from docosahexaenoic acid / DHA, the major omega-3 fatty acid in the brain.

Hemopressin

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

Hemopressin is a recently discovered endocannabinoid that acts as a CB1 inverse agonist (roughly meaning that it has the opposite action of THC at

PALDA

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

PALDA is an endocannabinoid with weak CB1 affinity.

Virodhamine

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

Suspected endocannabinoid.

VDHP

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

VDHP is a recently discovered endocannabinoid that acts as a CB1 agonist.

2OG

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

Suspected endocannabinoid. Does not bind classical endocannabinoid receptors (CB1/2) but targets GPR119.  

EPEA

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

Suspected endocannabinoid.

STEARDA

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

STEARDA is an endocannabinoid with weak CB1 affinity.

OLDA

Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14

OLDA is an endocannabinoid that weakly binds CB1 and GPR119 but has high affinity for TRPV1.